Last reviewed · How we verify
Ondansetron intravenous
Ondansetron intravenous is a Small molecule drug developed by Tanta University. It is currently in Phase 1 development.
At a glance
| Generic name | Ondansetron intravenous |
|---|---|
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Neutropenia
- Fatigue
- Constipation
- Nausea
- Headache
- Paraesthesia
- Vomiting
- Peripheral sensory neuropathy
- Anorexia
- Neuropathy peripheral
- Decreased appetite
Key clinical trials
- Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- Dexamethasone vs Ondansetron After Cesarean Delivery (PHASE4)
- Evaluation of Postoperative Pain Control in Ear Surgery (NA)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ondansetron intravenous CI brief — competitive landscape report
- Ondansetron intravenous updates RSS · CI watch RSS
- Tanta University portfolio CI
Frequently asked questions about Ondansetron intravenous
What is Ondansetron intravenous?
Ondansetron intravenous is a Small molecule drug developed by Tanta University.
Who makes Ondansetron intravenous?
Ondansetron intravenous is developed by Tanta University (see full Tanta University pipeline at /company/tanta-university).
What development phase is Ondansetron intravenous in?
Ondansetron intravenous is in Phase 1.
What are the side effects of Ondansetron intravenous?
Common side effects of Ondansetron intravenous include Diarrhoea, Neutropenia, Fatigue, Constipation, Nausea, Headache.
Related
- Manufacturer: Tanta University — full pipeline
- Compare: Ondansetron intravenous vs similar drugs
- Pricing: Ondansetron intravenous cost, discount & access